signal peptide peptidase like 3Genealiases: IMP2 · MDHV1887 · PRO4332 · PSH1 · PSL4
Q-omics provides the consensus-scored SPPL3 profile across patient tissues and cancer cell-line models. SPPL3 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, SPPL3 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, SPPL3 RNA expression shows 20,108 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight LIHC, HNSC, and ACC as cancer lineages where SPPL3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SPPL3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SPPL3 survival associations across molecular data types. SPPL3 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (6) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SPPL3 RNA expression–survival associations across cancer types. High SPPL3 expression shows unfavorable associations in LIHC, ACC and LUAD, but favorable associations in BRCA, UCS and KIRC. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for SPPL3 RNA expression.
This table summarizes SPPL3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 3. The strongest signals are observed in HNSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for SPPL3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SPPL3 shows lower tumor expression in THCA and higher tumor expression in HNSC, LIHC, KIRP, LUSC and KIRC. The HNSC box plot shows higher SPPL3 RNA expression in tumor versus normal tissue (log2 FC = +0.661, t-test p < 0.001).
This table shows molecular features associated with SPPL3 in patient tissues and cancer cell lines. In patient samples, SPPL3 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, SPPL3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and CNS.
